Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + MRG003
- Development stage
- Phase 2
- Lead developer
- Lepu Biopharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of pembrolizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, and MRG003 (becotatug vedotin), an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR). Pembrolizumab, developed by Merck, acts as a checkpoint inhibitor to enhance the immune system's anti-tumor response. MRG003, developed by Lepu Biopharma, consists of an anti-EGFR humanized IgG1 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a valine-citrulline linker. This combination is being investigated as a neoadjuvant and adjuvant treatment in a Phase II trial conducted by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology for patients with Epstein-Barr virus (EBV)-associated locoregionally advanced nasopharyngeal carcinoma.
- Other names
- pembrolizumab + becotatug vedotin
02
Targets
EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + MRG003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + MRG003.